Success Stories: From Lab to Clinic: Researcher Wins NIW for Cancer Immunotherapy Advances
Client’s Testimonial:
“Thank you so much for your help-it was only with your help that I was able to receive my EB2-NIW I-140 approval so smoothly.”
On September 10th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Staff Scientist in the Field of Tumor Immunology (Approval Notice).
General Field: Tumor Immunology
Position at the Time of Filing: Staff Scientist
Country of Origin: Taiwan
State of Residence at the Time of Filing: Oklahoma
Approval Notice Date: September 10th, 2025
Processing Time: 1 month, 3 days (Premium Processing Requested)
Case Summary:
Cancer remains one of the greatest public health challenges of our time, and the burden is especially severe for patients with treatment-resistant and rare cancers. These cases often lack effective therapies, leading to poor clinical outcomes and high healthcare costs.
An immunology researcher has dedicated his career to addressing this need by creating advanced preclinical cancer models that evaluate the efficacy and immune responses of novel immunotherapies. His work involves cancer vaccines, antibody-drug conjugates (ADCs), and rational combination strategies designed to improve treatment outcomes and expand options for patients with aggressive cancers. By optimizing these models, his research bridges the gap between laboratory discovery and clinical application, making therapies safer, more effective, and more widely accessible.
The significance of this research has already been recognized at the national level. His work has been supported by the Department of Defense’s Rare Cancers Research Program and Lung Cancer Research Program, as well as by the National Cancer Institute’s My Pediatric and Adult Rare Tumor Network (MyPART) and HealthBanks Biotech. Peers in the field have also praised his contributions.
As one expert explained, “[Client]'s work addresses this issue by identifying new targets for therapeutics and vaccines and determining the role of numerous cellular components in the proliferation of cancer within the body, thus helping U.S. clinicians develop more effective treatments and halt the rising rates of cancer diagnoses and deaths across America.”
Beyond securing competitive funding and endorsements, the researcher has built a solid record of scholarly achievement: 11 peer-reviewed journal articles (4 first-authored), 4 conference abstracts, 1 first-authored preprint, and at least 17 peer reviews for scientific journals. His work has been cited 260 times, further demonstrating its influence on the field of tumor immunology.
With this combination of impactful research, growing recognition, and proven qualifications, his petition for an EB-2 NIW was approved. NAILG carefully prepared and presented the case, resulting in this successful outcome. With his NIW approval, the researcher is now positioned to continue developing cutting-edge immunotherapies that can transform treatment strategies and improve outcomes for patients facing some of the most difficult cancer diagnoses.